Abstracts tagged "morbidity and mortality"

Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Ju Ann¹, Hyon K. Choi², Sharan K. Rai³, Eric C. Sayre⁴ and J Antonio Avina-Zubieta^5,6, ¹Experimental Mediine, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
Abstract Number: 909 • 2015 ACR/ARHP Annual Meeting
Smoking Behavior Changes after Rheumatoid Arthritis Diagnosis and Risk of Mortality during 36 Years of Prospective Follow-up
Jeffrey A. Sparks¹, Uyen Sa D.T. Nguyen^2,3, Shun-Chiao Chang^4,5, Yuqing Zhang⁶, Hyon Choi⁷ and Elizabeth W. Karlson⁴, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, ³Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁷Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Smoking is a major preventable cause of death and cessation is recommended for the general population. However, it is unclear whether being diagnosis with…
Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting
Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist¹, Tomas Jernberg², Solveig Wållberg-Jonsson³ and Johan Askling^4,5, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…
Abstract Number: 985 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study
Kateryna Vostretsova¹, Sharan K. Rai², Eric C. Sayre³, Hyon K. Choi⁴, JM Esdaile⁵ and J Antonio Avina-Zubieta⁶, ¹Rheumatology, Arthritis Research Centre, Vancouver, BC, Canada, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of mortality. However, recent mortality trends of SLE are unknown, particularly at the general…
Abstract Number: 2413 • 2015 ACR/ARHP Annual Meeting
Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) is associated with functional limitations, including difficulty walking. However, comorbid disease is common in people with OA and may also be associated…
Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting
Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice
Richard Bell¹, Ronald Wood², Joe Chakkalakal³, Christopher T. Ritchlin⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Pathology, University of Rochester, Rochester, NY, ²University of Rochester, Rochester, NY, ³Orthopaedics, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
Abstract Number: 3240 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Rheumatoid Arthritis: A General Population-Based Study
Na Lu^1,2, Hyon K. Choi³, Sara R. Schoenfeld³, Christine Peloquin⁴, Maureen Dubreuil⁵, Sharan K. Rai⁶, J Antonio Avina-Zubieta⁷ and Yuqing Zhang⁸, ¹Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Rheumatology, Boston VA HealthCare System, Boston, MA, ⁶Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁸BUSM, Boston, MA
Background/Purpose: All-cause mortality in UK has been decline by almost 20% over the past two decades. While rheumatoid arthritis (RA) is associated with an increased…
Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting
Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010
Eric Y Yen¹, Magda Shaheen², Jennifer MP Woo³, Deborah K. McCurdy⁴ and Ram Raj Singh⁵, ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CA, ³UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁵Medicine, UCLA Division of Rheumatology, Los Angeles, CA
Title: Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose: Many epidemiologic studies of systemic…
Abstract Number: 817 • 2014 ACR/ARHP Annual Meeting
Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years
I.M. Markusse¹, L. Dirven², J.H. van Groenendael³, K.H. Han⁴, H.K Ronday⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Fransiscus Hospital, Roosendaal, Netherlands, ⁴Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁵Rheumatology, Haga Hospital, The Hague, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of…
Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Anna-Maria Hoffmann-Vold¹, Oyvind Midtvedt², Torhild Garen³, May Brit Lund⁴, T. Mogens Aalokken⁵, Jan Tore Gran² and Oyvind Molberg⁶, ¹Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁵Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…
Abstract Number: 2997 • 2014 ACR/ARHP Annual Meeting
Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients
Robyn T. Domsic¹, Svetlana I. Nihtyanova², Mary Lucas³, Stephen R. Wisniewski⁴, Michael J. Fine⁵, C. Kent Kwoh⁶, Christopher P. Denton⁷ and Thomas A. Medsger Jr.⁸, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, ⁶1501 N. Campbell Avenue, Room 8303, The University of Arizona Arthritis Center, Tucson, AZ, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose : Knowledge of mortality risk and predictors is important in systemic sclerosis (SSc) patient care and clinical trial design. There is no validated 5-year…
Abstract Number: 3000 • 2014 ACR/ARHP Annual Meeting
Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity
Hebah Alhajeri¹, Marie Hudson^2,3, Canadian Scleroderma Research Group CSRG⁴ and Murray Baron⁵, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Division of Rheumatology, McGill University, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Identifying systemic sclerosis (SSc) subsets that predict mortality and morbidity could provide useful prognostic information. We undertook this study to compare the predictive ability…
Abstract Number: 2941 • 2014 ACR/ARHP Annual Meeting
Physical Function Is Independently Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project
Rebecca J. Cleveland¹, Todd Schwartz¹, Jordan B. Renner², Joanne M. Jordan³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Department of Radiology, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose Declining physical function (PF) is a common consequence of osteoarthritis (OA), and poor PF is associated with death. It is possible that the resulting…
Abstract Number: 2620 • 2014 ACR/ARHP Annual Meeting
Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to 2013
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Milagros Ricse¹, Gloria Albert¹, Eulalia Armengol¹, Helena Borrell¹, Olga Capdevila³, Francesca Mitjavila³, Toni Rozadilla¹, Xavier Juanola⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To study the mortality, survival and causes of death in a Spanish cohort of patients with systemic lupus erythematosus (SLE) over a 28-year period…
Abstract Number: 2188 • 2014 ACR/ARHP Annual Meeting
Incidence and Mortality of Relapsing Polychondritis in the United Kingdom: A Population-Based Cohort Study
Nisha Hazra¹, Alex Dregan¹, Judith Charlton¹, Martin C Gulliford¹ and David P. D'Cruz², ¹Division of Primary Care and Public Health Research, King's College London, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: To estimate the incidence, prevalence and mortality of Relapsing Polychondritis (RP), and to describe the clinical features of RP, in a large population. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.